Rep. David Taylor (R-OH) Buys Amgen (AMGN) Stock
House member David Taylor purchases Amgen shares valued between $1,001 and $15,000.
Reviewed by automated data checks against the source filing. How we make and check alerts
Rep. David Taylor (R-OH) bought between $1,001 and $15,000 of Amgen Inc. ($AMGN) stock on June 5, 2026. The trade was disclosed in a STOCK Act periodic transaction report filed June 15, 2026.
Since the trade, $AMGN is up 1.6% after 1 week, up 4.8% after 1 month and up 24.4% to date (from the $347.55 close on Jun 5, 2026).
Financial Disclosure Report
Clerk of the House of Representatives • Legislative Resource Center • B81 Cannon Building • Washington, DC 20515
Filer Information
- Name:
- Rep. David Taylor (R-OH)
- Status:
- Member — House
- State/District:
- OH-2
- Party:
- republican
Filing Information
- Filing Type:
- Periodic Transaction Report
- Filing Year:
- 2026
- Filing Date:
- Jun 15, 2026
Schedule B: Transactions
| Asset | Transaction | Date | Amount |
|---|---|---|---|
| Amgen Inc. ($AMGN) | Buy | Jun 5, 2026 | $1,001 - $15,000 |
Summary of the filed report, not the original document. Find the original: House financial disclosure search
AMGN
Amgen Inc.
Key Points
- David Taylor, a member of the House, bought Amgen shares valued between $1,001 and $15,000 on June 5, 2026.
- Amgen stock trades near $355.2 with a market cap of $191.7 billion and a forward P/E of 15.13.
- Analysts have set new price targets for Amgen, with Piper Sandler maintaining a 'buy' rating and a $427 target.
Get $AMGN trade alerts by text
We text you when insiders, Congress or big funds trade $AMGN. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Amgen Inc. alert may contain errors. Disclosures
David Taylor, a member of the U.S. House of Representatives, recently purchased shares of Amgen Inc. (NASDAQ: AMGN). The transaction, reported on June 15, 2026, involved buying shares valued between $1,001 and $15,000. This move adds a political figure to the list of investors in the healthcare giant.
David Taylor vs. the S&P 500
Hypothetical returns from David Taylor's disclosed trades, not real profit or advice. How we model this.
Other Institutional Activity in Amgen
Amgen has seen varying levels of interest from institutional investors. BlackRock, Inc. slightly trimmed its holdings by 295,666 shares, ending with 47,100,472 shares valued at about $16.57 billion. Vanguard Capital Management LLC made a significant addition, acquiring 35,014,232 shares, now holding the same amount worth approximately $12.32 billion. State Street Corp reduced its stake by 42,915 shares, leaving it with 30,548,488 shares valued at $10.75 billion. Meanwhile, Capital World Investors increased its position by 6,190,632 shares, totaling 29,288,343 shares worth about $10.30 billion.
Amgen Inc. Stock Down 15.8%
Shares of Amgen Inc. trade near $355.2. The company has a market capitalization of approximately $191.7 billion. It sports a P/E ratio of 24.68 and a forward P/E of 15.13, indicating expectations of future earnings growth. Amgen's stock has a 52-week low of $267.83 and a high of $391.29. The 50-day moving average is $340.31, while the 200-day moving average is $330.73. The company's beta is 0.416, suggesting lower volatility compared to the broader market.
Recent Earnings
Amgen reported a revenue of $37.22 billion, with a growth rate of 5.8%. The company's earnings per share (EPS) stand at $14.39, and it has a net margin of 20.96%. Return on equity (ROE) is a robust 101.32%. The next earnings report is expected on August 4, 2026.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
2 target cuts vs 1 raises.
-
EPS & revenue
EPS beat estimates by 6.1%. Revenue missed estimates by 1.5%.
-
Profit surprise
EBITDA missed by 45 percent. Operating income missed by 28 percent.
-
Pre-earnings setup
Expectations were about average.
-
Analyst signal
1 target raise, 2 target cuts.
-
Earnings quality
Gross margin up 4.6 points. Operating margin up 16.5 points. Positive free cash flow.
Earnings Call Summary
Amgen had a strong first quarter with earnings per share of 5.15 dollars beating expectations of 4.73 dollars. Six key medicines grew sales by 24 percent year over year and now make up 70 percent of total sales. The obesity drug Meritide is advancing well in late-stage testing with new studies showing better tolerance when patients take it less frequently, potentially every eight to twelve weeks instead of weekly injections.
Guidance Amgen raised its 2026 outlook to revenue between 37.1 billion and 38.5 billion dollars, and earnings per share between 21.70 and 23.10 dollars. The company expects its fast-growing medicines like Repatha and Evenity to offset patent losses. Management said capital spending will remain at about 2.6 billion dollars to scale manufacturing for new drug launches.
Clearly negative report. The company missed important expectations and likely triggers downward revisions.
Dividend
Amgen offers an annual dividend rate of $10.08, yielding 2.84%. The dividend payout ratio is 67.22%, indicating a healthy distribution of profits back to shareholders.
Insider Buying and Selling at Amgen Inc.
Several insiders purchased shares on May 19, 2026. Charles Holley, Ellen Jamison Kullman, Greg Garland, Wanda Austin, Brian Druker, and Tyler Jacks each bought 665 shares. These transactions were not part of a pre-planned trading program.
Analysts Set New Price Targets
On June 10, 2026, Morgan Stanley maintained a 'hold' rating with a $340 price target. Piper Sandler, on May 14, 2026, reaffirmed a 'buy' rating with a target of $427. The consensus rating for Amgen is a 'buy', with a mean target price of $352.5 from 30 analysts.
About Amgen
Amgen Inc., headquartered in Thousand Oaks, California, is a leading biotechnology company in the healthcare sector. It specializes in discovering, developing, manufacturing, and delivering human therapeutics. The company is known for products like Enbrel, Otezla, and Prolia, which treat a range of conditions from arthritis to osteoporosis. With over 31,500 employees, Amgen operates globally and partners with other major firms to expand its product offerings.
Bottom Line
David Taylor's purchase of Amgen shares highlights ongoing interest in this major biotechnology firm. With substantial institutional activity and analyst attention, Amgen remains a significant player in the healthcare market. Remember, the disclosed trades reflect past actions and may not indicate current holdings.
Related Filing Alerts
Source: David Taylor's STOCK Act disclosure on $AMGN (Jun 5, 2026). Find the original filing: House financial disclosure search. Written by software, not financial advice. How we make alerts